enGene Therapeutics Inc. ENGN
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -130.36M | -126.85M | -122.44M | -117.30M | -94.72M |
| Total Depreciation and Amortization | 718.00K | 670.00K | 596.00K | 509.00K | 421.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 17.91M | 12.13M | 9.59M | 7.81M | 6.87M |
| Change in Net Operating Assets | 8.42M | 4.06M | 9.80M | 9.74M | -6.42M |
| Cash from Operations | -103.31M | -110.00M | -102.45M | -99.24M | -93.85M |
| Capital Expenditure | -688.00K | -1.39M | -1.34M | -1.49M | -1.29M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -31.35M | -59.39M | -65.13M | -23.65M | -189.62M |
| Cash from Investing | -32.04M | -60.78M | -66.47M | -25.14M | -190.90M |
| Total Debt Issued | 25.00M | 25.00M | 25.00M | -- | 0.00 |
| Total Debt Repaid | -23.05M | -23.75M | -23.75M | -699.00K | -699.00K |
| Issuance of Common Stock | 151.79M | 151.80M | 152.00M | 2.22M | 60.39M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -9.99M | -9.99M | -10.06M | -- | 0.00 |
| Cash from Financing | 143.75M | 143.06M | 143.18M | 1.52M | 59.69M |
| Foreign Exchange rate Adjustments | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 8.40M | -27.72M | -25.73M | -122.85M | -225.06M |